Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 2 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Nine-valent human papillomavirus vaccine shows favourable safety profile

26 Dec 2019

Safety data of the 9-valent human papillomavirus vaccine (9vHPV) from the Vaccine Adverse Event Reporting System (VAERS) during the first 3 years of its licensure in the United States have shown neither new or unexpected safety signals, nor unusual reporting patterns for clinically important adverse events (AEs), as reported in a study. Furthermore, the safety profile of the vaccine is similar to that of its quadrivalent predecessor.

VAERS documented 7,244 AEs following receipt of 9vHPV. Of the AEs, 31.2 percent occurred among females and 21.6 percent among males; sex was not reported in 42.7 percent.

Majority (97.4 percent) of the AEs were nonserious, the most common being dizziness, syncope, headache and injection site reactions. These AEs occurred with similar frequency in men and women. There were two verified cases of deaths post-9vHPV treatment, although autopsy reports or death certificates suggested no evidence of a causal relationship with vaccination.

Roughly 28 million 9vHPV doses were administered during the study period, giving crude AE reporting rates of 259 reports per million doses distributed for all reports and 7 per million doses distributed for serious reports.

Empirical Bayesian data mining findings showed a significant association between 9vHPV and syncope and several types of vaccine administration errors (eg, administered at wrong age).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 3 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 3 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 2 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.